Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings - POTOMAC, MARYLAND / ACCESS Newswire / July 23, 2025 /IGC Pharma ...

Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of Alzheimer's and all other ...

The first clinical guideline on the use of blood biomarker tests could help clinicians choose the most appropriate test to ...

Adopting intensive lifestyle changes can slow or stop progression of early-stage Alzheimer’s disease, according to a new ...

Traditionally, the diagnosis of Alzheimer’s disease has been based on informant interviews and clinical assessments of memory, cognition, behaviour, and mood. To increase diagnostic confidence, ...

Serum levels of C1M, a biochemical marker of type I collagen degradation, may predict progression of total joint damage in patients with early arthritis.

A major Alzheimer’s disease medical group is recommending that specialists may use certain blood tests to help diagnose ...

Current methods for cancer diagnosis are based on identifying biomarkers—molecules that reveal a particular state or process ...

Marilyn Glassberg, MD, emphasizes the need for improved community education and highlights promising new drug pathways for idiopathic pulmonary fibrosis (IPF).

This technology enables the high-sensitivity detection of trace amounts of cancer DNA without any pre-processing, making it highly competitive for use in the early cancer diagnosis market.